- Home
- DV vs BEAM Comparison
DV vs BEAM Comparison
Compare DV & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DV
- BEAM
- Stock Information
- Founded
- DV 2008
- BEAM 2017
- Country
- DV United States
- BEAM United States
- Employees
- DV N/A
- BEAM N/A
- Industry
- DV Computer Software: Prepackaged Software
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DV Technology
- BEAM Health Care
- Exchange
- DV Nasdaq
- BEAM Nasdaq
- Market Cap
- DV 2.2B
- BEAM 1.8B
- IPO Year
- DV 2021
- BEAM 2020
- Fundamental
- Price
- DV $13.73
- BEAM $15.83
- Analyst Decision
- DV Buy
- BEAM Strong Buy
- Analyst Count
- DV 18
- BEAM 11
- Target Price
- DV $19.08
- BEAM $48.90
- AVG Volume (30 Days)
- DV 3.0M
- BEAM 2.0M
- Earning Date
- DV 05-08-2025
- BEAM 05-06-2025
- Dividend Yield
- DV N/A
- BEAM N/A
- EPS Growth
- DV N/A
- BEAM N/A
- EPS
- DV 0.29
- BEAM N/A
- Revenue
- DV $681,128,000.00
- BEAM $63,578,000.00
- Revenue This Year
- DV $13.59
- BEAM N/A
- Revenue Next Year
- DV $11.88
- BEAM $10.59
- P/E Ratio
- DV $46.99
- BEAM N/A
- Revenue Growth
- DV 15.30
- BEAM N/A
- 52 Week Low
- DV $11.52
- BEAM $13.53
- 52 Week High
- DV $23.11
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- DV 50.33
- BEAM 36.15
- Support Level
- DV $13.09
- BEAM $16.61
- Resistance Level
- DV $15.26
- BEAM $17.47
- Average True Range (ATR)
- DV 0.43
- BEAM 0.91
- MACD
- DV -0.06
- BEAM -0.08
- Stochastic Oscillator
- DV 29.49
- BEAM 12.63
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.